which glp-1 agonists have cardiovascular benefit Glucagon-like peptide 1 receptor agonists: benefits and mechanisms of action Frontiers | The benefits of
Description
The study was a secondary data analysis and did not include patients as study participants
Uddman, B
doi: 10.1136/bmjopen-2012-001986
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept
Notably, 48% of participants planned to take GLP-1RA indefinitely
The scales used were the Mini-Mental State Examination (MMSE) and the Wechsler Memory ScaleFourth Edition (WMS-IV)
